2. Signaling Pathways
  3. Immunology/Inflammation
  4. NO Synthase
  5. iNOS Isoform

iNOS

iNOS, also known as NOS-2, is a 131 kDa mammalian protein composed of 1,153 amino acids, which are assembled into two major domains, a C-terminal reductase—containing a flavin mononucleotide (FMN) binding subdomain—and a N-terminal oxygenase.iNOS adopts a zinc-bridged, homodimeric quaternary structure that allows the enzyme to convert L-Arg to L-citrulline with the concomitant production of NO. This transformation is governed by an elaborate electron transport chain, involving the cofactors nicotinamide adenine dinucleotide phosphate (NADPH), flavin adenine dinucleotide (FAD), flavin mononucleotide (FMN), heme, and (6R)-5,6,7,8-tetrahydrobiopterin (H4B), which are essential for this reaction. This process is mediated by CaM, which binds in a hinge region between the oxygenase and reductase domains.

iNOS Related Products (74):

Cat. No. Product Name Effect Purity
  • HY-146161
    COX-2/NO-IN-1
    		Inhibitor
    COX-2/NO-IN-1 is an orally active nitric oxide synthase (iNOS), COX-2 expression and NO (IC50 of 3.52 μM) inhibitor. COX-2/NO-IN-1 has anti-inflammatory effects.
  • HY-N3848
    Ermanin
    		Inhibitor
    Ermanin is a flavonoid isolated from Tanacetum microphyllum. Ermanin potently inhibits iNOS, COX-2 activities, and inhibits platelet aggregation. Ermanin has anti-inflammatory, anti-tuberculous and anti-viral/bacterial properties.
  • HY-N3364
    Lucidone
    		Inhibitor
    Lucidone, an anti-inflammatory agent that can be isolated from the fruit of Lindera erythrocarpa Makino. Lucidone inhibits LPS-induced NO and PGE2 production in RAW 264.7 mouse macrophages. Lucidone also decreases TNF-α secretion, iNOS and COX-2 expression. Lucidone prevents NF-κB translocation and inhibits JNK and p38MAPK signals. Lucidone also has inhibitory activity against Dengue virus (DENV) (EC50=25 μM).
  • HY-162805
    iNOS/TopoI-IN-1
    		Inhibitor
    iNOS/TopoI-IN-1 (compound AuL9) is a multi-target hybrid molecule with anti-tumor, anti-inflammatory and antioxidant activities. iNOS/TopoI-IN-1 inhibits the growth of breast cancer cells MCF-7 and MDA MB-231 in vitro with IC50 of 3.5 μM and 6.3 μM, respectively, and induces DNA damage and apoptosis of breast cancer cells by inhibiting human topoisomerase I (TopoI) (Ki=2.72 μM). In addition, NOS/TopoI-IN-1 inhibits the expression of iNOS by inhibiting the activation of NF-kB (Ki=1.49 μM).
  • HY-158334
    NDs-IN-1
    		Inhibitor
    (Neurodegenerative diseases) NDs-IN-1 (Compound 3g) inhibits the activities of key enzymes such as hBACE-1, hAChE and hMAO-B. NDs-IN-1 is a novel non-covalent multi-target inhibitor. NDs-IN-1 is mainly used in the study of neurodegenerative diseases.
  • HY-N10156
    1,3,5-Trihydroxy-4-prenylxanthone
    		Inhibitor
    1,3,5-Trihydroxy-4-prenylxanthone is a Na+/H+ exchange system (Na+/H+ Exchanger (NHE)) inhibitor with a minimum inhibitory concentration of 10 μg/mL. 1,3,5-Trihydroxy-4-prenylxanthone is a phosphodiesterase type 5 (PDE5) (Phosphodiesterase (PDE)) inhibitor with an IC50 value of 3.0 μM. 1,3,5-Trihydroxy-4-prenylxanthone inhibits Lipopolysaccharide (LPS) (Lipopolysaccharides (HY-D1056))-induced NO production in RAW264.7 macrophages, and has anti-inflammatory activities.
  • HY-101318
    β-Funaltrexamine hydrochloride
    		Inhibitor
    β-Funaltrexamine (β-FNA) hydrochloride is a selective μ opioid receptor antagonist. β-Funaltrexamine hydrochloride also inhibits cytokine-induced iNOS activation. β-Funaltrexamine hydrochloride inhibits neuroinflammation and ameliorated neuronal degeneration. β-Funaltrexamine hydrochloride has anti-inflammatory and neuroprotective effects and can be used for research of neurodegenerative diseases (eg: stroke)[1][2]
  • HY-168096
    iNOs-IN-5
    		Inhibitor
    iNOs-IN-5 (Compound BN-4) is an inhibitor for iNOS with an IC50 of 0.1707 μM, and reduces NO levels in LPS (HT-D1056)-induced RAW264.7 cells. iNOs-IN-5 reduces the hypoxic injury stimulated ROS and lactate dehydrogenase expression, and exhibits anti-necrosis and anti-apoptosis efficacy. iNOs-IN-5 exhibits anti-cerebral ischemia and neuroprotective activities in SD rat models. iNOs-IN-5 is blood-brain barrier penetrable.
  • HY-115916
    NOS-IN-2
    		Inhibitor
    NOS-IN-2 (Compound 4i) is a potent, selective, imidamide derived NOS inhibitor with an IC50 against iNOS of 20 µM, without inhibiting eNOS. NOS-IN-2 has little toxicity and can be used for studying inflammatory disorders.
  • HY-149496
    Akt/NF-κB/MAPK-IN-1
    		Inhibitor
    Akt/NF-κB/MAPK-IN-1 (compound 2m) is a potent and orally active inhibitor against NO (IC50=7.70 μM) with no significant toxicity. Akt/NF-κB/MAPK-IN-1 shows anti-inflammatory activity by inhibiting Akt/NF-κB and MAPK signaling pathways.
  • HY-135224
    1,4-PBIT dihydrobromide
    		Inhibitor
    1,4-PBIT (1,4-PB-ITU) dihydrobromide (compound 46) is a potent nitric oxide synthases (NOS) inhibitor, with Ki values of 7.6 nM, 360 nM, and 16 nM for the inducible (iNOS), endothelial (eNOS), and neuronal (nNOS) isozymes, respectively.
  • HY-115917
    NOS-IN-3
    		Inhibitor
    NOS-IN-3 (Compound 9a) is a potent, selective, imidamide derived NOS inhibitor with an IC50 against iNOS of 4.6 μM, without inhibiting eNOS. NOS-IN-3 has little toxicity and can be studied in the research of inducible isoform involved diseases, such as septic shock.
  • HY-122063
    FR260330
    		Inhibitor
    FR260330 is a selective, orally active inhibitor for inducible nitric oxide synthase (iNOS) through suppression of iNOS dimerization. FR260330 inhibits the NO accumulation in rat splenocytes and human DLD-110 cells, with IC50 of 27 and 10 nM. FR260330 ameliorates the Lipopolysaccharides (HY-D1056)-induced inflammatory diseases in rats model.
  • HY-115410
    NG-Amino-L-arginine hydrochloride
    		Inhibitor
    NG-Amino-L-arginine hydrochloride induces inactivation of the citrulline-forming activity of the nNOS, iNOS, and eNOS isoforms with Ki values of 0.3 μM, 3 μM, and 2.5 μM, respectively.